A Chemical Linker for Attaching Drugs to Antibodies
This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.
Patent Number
US 10772965
Status
Active
Filing Date
February 14, 2018
Grant Date
September 15, 2020
Expiration
February 14, 2038
Claims
3
Assignee
Rc Biotechnologies
Inventors
Lezhi ZHANG, Hui Ye, Jianmin Fang, Changjiang Huang
Citations
1 forward · 15 backward
What it covers
This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.
What it doesn't cover
- —Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
- —Linkers that do not conform to the specific chemical structure of Formula I as described in claim 1.
- —Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
- —Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claim 1.
- —Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.
The clever bit
The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.
Why it matters
This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.
Real-world examples
- 1.Kadcyla (trastuzumab emtansine)
- 2.Adcetris (brentuximab vedotin)
- 3.Enhertu (trastuzumab deruxtecan)
- 4.Trodelvy (sacituzumab govitecan)
- 5.Padcev (enfortumab vedotin)
Generated by PatentBrief · Not legal advice · patentbrief.org
US 10772965 · 2026